Evidence map›Paper›PMID 41943606›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Myelin oligodendrocyte glycoprotein antibody-associated disease and relapse risk: Effects of smoking and vascular risk factors.

Wei Zhen Yeh, Fiona Chan, Anna Francis, Helmut Butzkueven, Ruth Geraldes, Maria Isabel Leite, Jacqueline Palace

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei Zhen YehNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Health, Melbourne, VIC, Australia.ORCID 0000-0002-5335-6612
Fiona ChanNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID 0000-0002-7380-7783
Anna FrancisNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Helmut ButzkuevenDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Health, Melbourne, VIC, Australia.ORCID 0000-0003-3940-8727
Ruth GeraldesNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID 0000-0001-5829-808X
Maria Isabel LeiteNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Jacqueline PalaceNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effects of smoking and vascular risk factors (VRF) on relapse activity in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are not well understood. We aimed to investigate these.

methodsMOGAD patients in the Oxford National Neuromyelitis Optica (NMO) Service with known smoking or VRF (hypertension, hypercholesterolaemia, type 2 diabetes, elevated body mass index) status were considered for inclusion. Outcomes were time-to-relapsing course and relapse rate. Cox and negative binomial regression were utilised.

resultsWe included 172 patients. Current smokers had a 2.2 times higher relapse rate than never smokers (adjusted rate ratio 2.23 [95% CI = 1.35-3.68],

conclusionRelapse rates were doubled in current than never smokers, whereas these were similar between past and never smokers. VRF did not associate with relapse risk. Smoking cessation should be encouraged in current smokers with MOGAD as past smokers were not observed with this poorer outcome.

Indexed as

Myelin-Oligodendrocyte GlycoproteinMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseSmokingAdultFemaleHumansMaleMiddle AgedRecurrenceRisk FactorsMyelin-Oligodendrocyte GlycoproteinMOGADMyelin oligodendrocyte glycoprotein antibody-associated diseaserelapsesmokingvascular risk factors

Identifiers

PMID41943606
PMCPMC13333031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.